Zacks Research Has Bearish Forecast for STERIS Q2 Earnings

STERIS plc (NYSE:STE) – Research analysts at Zacks Research lowered their Q2 2026 earnings per share estimates for STERIS in a research note issued to investors on Wednesday, June 4th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $2.35 for the quarter, down from their previous estimate of $2.36. The consensus estimate for STERIS’s current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS’s FY2028 earnings at $11.93 EPS.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.15. The company had revenue of $1.48 billion during the quarter, compared to the consensus estimate of $1.47 billion. STERIS had a return on equity of 13.91% and a net margin of 8.66%. STERIS’s revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the business posted $2.58 earnings per share.

Several other equities analysts also recently weighed in on STE. Citigroup reissued an “outperform” rating on shares of STERIS in a research report on Friday, May 16th. Jefferies Financial Group started coverage on STERIS in a research report on Thursday, May 29th. They issued a “hold” rating and a $263.00 price objective for the company. Stephens reaffirmed an “overweight” rating and issued a $250.00 price objective on shares of STERIS in a research report on Thursday, May 15th. Morgan Stanley lifted their price objective on STERIS from $240.00 to $260.00 and gave the company an “equal weight” rating in a research report on Monday, May 19th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Monday, April 7th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $263.83.

STERIS Stock Performance

STERIS stock opened at $243.71 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.40 and a current ratio of 2.13. The stock has a fifty day moving average of $230.25 and a two-hundred day moving average of $221.76. The company has a market capitalization of $23.97 billion, a price-to-earnings ratio of 51.74 and a beta of 0.94. STERIS has a fifty-two week low of $200.98 and a fifty-two week high of $252.79.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 26th. Investors of record on Tuesday, June 10th will be issued a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 0.94%. The ex-dividend date is Tuesday, June 10th. STERIS’s dividend payout ratio is currently 36.77%.

Insider Activity at STERIS

In other news, CEO Daniel A. Carestio sold 17,626 shares of the company’s stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $242.56, for a total transaction of $4,275,362.56. Following the completion of the transaction, the chief executive officer now directly owns 51,385 shares of the company’s stock, valued at approximately $12,463,945.60. This represents a 25.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Cary L. Majors sold 12,828 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $250.08, for a total value of $3,208,026.24. Following the completion of the transaction, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at $2,843,909.76. This trade represents a 53.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On STERIS

A number of institutional investors and hedge funds have recently added to or reduced their stakes in STE. Geneos Wealth Management Inc. lifted its position in STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares during the period. Avalon Trust Co acquired a new stake in STERIS in the fourth quarter worth approximately $30,000. Grove Bank & Trust lifted its position in STERIS by 4,733.3% in the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 142 shares during the period. Human Investing LLC acquired a new stake in shares of STERIS during the 4th quarter valued at $31,000. Finally, Zions Bancorporation National Association UT acquired a new stake in shares of STERIS during the 1st quarter valued at $37,000. 94.69% of the stock is owned by institutional investors.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.